Argenix expects five potential launches, with IM&M the largest growth contributor, and plans continued disciplined business development. It also announced the UNP acquisition, subject to customary closing conditions, while expecting revenue growth to exceed OPEX growth.
ARGX · Argenx SE
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
argenx said the Phase 3 ALKIVIA study of efgartigimod met primary and key secondary endpoints in combined IMNM and DM populations; it plans to submit an sBLA for IMNM by the end of 2026.
argenx will acquire all remaining shares of Unnatural Products, Inc. (UNP), with $550 million upfront and up to $595 million in development and regulatory milestone payments; closing is expected by the end of the year.
Argenix reported product net sales of $1.7 billion, up 54% year-over-year, and expects up to five U.S. launches in 2027. It plans an IM&M filing by year-end and an MMN Phase III readout in December.
argenx SE generated third-quarter VYVGART net sales of $1.7 billion, up 54% year-over-year, and profit of $0.5 billion. VYVGART Hytrulo’s IMNM sBLA is on track for submission by year-end 2026; empasiprubart Phase 3 MMN data are expected in December 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARGX
this stock
Argenx SE
|
$59.80B | +13.1% | — | — | 2.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.35B | +18.6% | +46.2% | 34.6 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.52B | +23.4% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.08B | +630.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$65.26B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 40
Argenix expects five potential launches, with IM&M the largest growth contributor, and plans continued disciplined business development. It also announced the UNP acquisition, subject to customary closing conditions, while expecting revenue growth to exceed OPEX growth.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARGX | -1.2% | +15.2% | +15.9% | +6.5% | +13.1% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | +0.5% | +18.6% | +17.3% | +8.6% | +4.6% |